SARS-CoV-2血清学检测是否应用于决定接种COVID-19疫苗加强针?利弊评估
抗SARS-CoV-2疫苗接种在过去几年拯救了数百万生命。为维持高水平保护,尤其在高危人群中,推荐加强针以应对循环抗体水平随时间下降和免疫逃逸变异株(VOC)的不断出现。由于抗刺突血清学现已广泛可用,可考虑将其作为识别需要额外疫苗剂量个体的工具。然而,目前尚无相关推荐。我们回顾了相关支持与反对论点及不确定性领域,结论是在大多数人群中,不应使用刺突血清学来决定加强针接种。
要点
- 在大多数人群中,不应使用刺突血清学来决定是否接种加强针。
- 保护 correlates 表征不完善,主要因 VOC 出现。
- 刺突血清学无法全面反映整个免疫记忆。
核心结论
- 在大多数人群中,不应使用刺突血清学来决定加强针接种。
研究设计与样本
- 本文为利弊评估(pro-con assessment),回顾相关支持与反对论点及不确定性领域。
主要发现
- 抗SARS-CoV-2疫苗接种在过去几年拯救了数百万生命。
- 推荐加强针以应对循环抗体水平随时间下降和免疫逃逸VOC的不断出现。
- 抗刺突血清学现已广泛可用,可考虑用于识别需要额外疫苗剂量的个体。
- 目前尚无关于此主题的推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 保护 correlates 表征不完善,主要因 VOC 出现。
- 刺突血清学内在无法全面反映整个免疫记忆。
- 加强针已适应 VOC,而常用商业血清学检测针对原始病毒抗体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-SARS-CoV-2 vaccination has saved millions of lives in the past few years. To maintain a high level of protection, particularly in at-risk populations, booster doses are recommended to counter the waning of circulating antibody levels over time and the continuous emergence of immune escape variants of concern (VOCs). As anti-spike serology is now widely available, it may be considered a useful tool to identify individuals needing an additional vaccine dose, i.e., to screen certain populations to identify those whose plasma antibody levels are too low to provide protection. However, no recommendations are currently available on this topic. We reviewed the relevant supporting and opposing arguments, including areas of uncertainty, and concluded that in most populations, spike serology should not be used to decide about the administration of a booster dose. The main counterarguments are as follows: correlates of protection are imperfectly characterised, essentially owing to the emergence of VOCs; spike serology has an intrinsic inability to comprehensively reflect the whole immune memory; and booster vaccines are now VOC-adapted, while the commonly available commercial serological assays explore antibodies against the original virus.
引用
- Augello M, Wagenhäuser I, Krone M, et al. Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment. Vaccine. 2024. PMID: 39097440. doi:10.1016/j.vaccine.2024.126184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。